203 related articles for article (PubMed ID: 16342902)
1. Pelvic irradiation-induced eosinophilia is correlated to prognosis of cervical cancer patients and transient elevation of serum interleukin 5 level.
Yamazaki H; Inoue T; Tanaka E; Isohashi F; Koizumi M; Shuo X; Nakamura H; Inoue T
Radiat Med; 2005 Aug; 23(5):317-21. PubMed ID: 16342902
[TBL] [Abstract][Full Text] [Related]
2. [Studies on serum protein fractions of patients with uterine cervical cancer undergoing radiotherapy: relationship between changes in serum protein fractions and prognosis].
Onizuka K; Migita S; Yamada H; Uwada O; Umemura Y; Kuroki M; Tateyama H
Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Sep; 54(10):1007-17. PubMed ID: 7971179
[TBL] [Abstract][Full Text] [Related]
3. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
4. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies.
Kasibhatla M; Clough RW; Montana GS; Oleson JR; Light K; Steffey BA; Jones EL
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):398-403. PubMed ID: 16542793
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract].
An JS; Wu LY; Li N; Li B; Yu GZ; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):320-4. PubMed ID: 17673044
[TBL] [Abstract][Full Text] [Related]
6. High dose-rate intracavitary brachytherapy for cervical carcinomas with lower vaginal infiltration.
Kazumoto T; Kato S; Tabushi K; Kutsutani-Nakamura Y; Mizuno H; Takahashi M; Shiromizu K; Saito Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1157-66. PubMed ID: 17459604
[TBL] [Abstract][Full Text] [Related]
7. Effect of radiotherapy on serum level of interleukin 6 in patients with cervical carcinoma.
Tang JT; Yamazaki H; Nishimoto N; Inoue T; Nose T; Koizumi M; Tanaka E; Ogata A; Yoshizaki K; Inoue T
Anticancer Res; 1996; 16(4A):2005-8. PubMed ID: 8712734
[TBL] [Abstract][Full Text] [Related]
8. The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone.
Grigiene R; Valuckas KP; Aleknavicius E; Kurtinaitis J; Letautiene SR
BMC Cancer; 2007 Dec; 7():234. PubMed ID: 18154683
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-guided interstitial brachytherapy in the treatment of advanced vaginal recurrences from cervical and endometrial carcinoma.
Weitmann HD; Knocke TH; Waldhäusl C; Pötter R
Strahlenther Onkol; 2006 Feb; 182(2):86-95. PubMed ID: 16447015
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract][Full Text] [Related]
11. Radical radiotherapy with high-dose-rate brachytherapy for uterine cervix cancer long-term results.
Khor TH; Tuan JK; Hee SW; Tham IW
Australas Radiol; 2007 Dec; 51(6):570-7. PubMed ID: 17958695
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.
Liang JA; Chen SW; Chang WC; Hung YC; Yeh LS; Yang SN; Lin FJ
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):683-90. PubMed ID: 18676129
[TBL] [Abstract][Full Text] [Related]
13. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial infusion chemotherapy using cisplatin with radiotherapy for Stage III squamous cell carcinoma of the cervix.
Kaneyasu Y; Nagai N; Nagata Y; Hashimoto Y; Yuki S; Murakami Y; Kenjo M; Kakizawa H; Toyota N; Fujiwara H; Kudo Y; Ito K
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):369-77. PubMed ID: 19735865
[TBL] [Abstract][Full Text] [Related]
15. [Impact of squamous cell carcinoma antigen in patients with recurrent squamous cell carcinoma of the uterine cervix].
Ma SK; Wu LY; Sun YC; Li B; Zhang HT
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):13-7. PubMed ID: 18366925
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.
Novetsky AP; Einstein MH; Goldberg GL; Hailpern SM; Landau E; Fields AL; Mutyala S; Kalnicki S; Garg M
Gynecol Oncol; 2007 Jun; 105(3):635-40. PubMed ID: 17331568
[TBL] [Abstract][Full Text] [Related]
17. Intestinal complications of pelvic irradiation for gynecologic cancer.
Smith AN; Douglas M; McLean N; Ruckley CV; Bruce J
Surg Gynecol Obstet; 1968 Oct; 127(4):721-8. PubMed ID: 5675187
[No Abstract] [Full Text] [Related]
18. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya VT; Tatsuzaki H
Radiother Oncol; 2007 Jan; 82(1):24-9. PubMed ID: 17161478
[TBL] [Abstract][Full Text] [Related]
19. [Recurrence of gynecologic malignancies after combined and primary radiotherapy. Incidence and lapse of time until the diagnosis is made].
Csaicsich P; Tatra G; Michalica W
Strahlenther Onkol; 1986 Jul; 162(7):409-13. PubMed ID: 3738739
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy.
Yoshimura R; Hayashi K; Ayukawa F; Toda K; Iwata M; Oota S; Hoshi A; Wakatsuki M; Kurosaki H; Okazaki A; Shibuya H
Brachytherapy; 2008; 7(3):260-6. PubMed ID: 18579445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
